Correlation Between HCW Biologics and Mineralys Therapeutics,

Can any of the company-specific risk be diversified away by investing in both HCW Biologics and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining HCW Biologics and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between HCW Biologics and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on HCW Biologics and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in HCW Biologics with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of HCW Biologics and Mineralys Therapeutics,.

Diversification Opportunities for HCW Biologics and Mineralys Therapeutics,

-0.26

Correlation Coefficient

HCW Biologics  Mineralys Therapeutics,

Very good diversification

The 3 months correlation between HCW and Mineralys is -0.26. Overlapping area represents the amount of risk that can be diversified away by holding HCW Biologics and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and HCW Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on HCW Biologics are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of HCW Biologics i.e., HCW Biologics and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between HCW Biologics and Mineralys Therapeutics,

Given the investment horizon of 90 days HCW Biologics is expected to generate 1.74 times less return on investment than Mineralys Therapeutics,. In addition to that, HCW Biologics is 2.41 times more volatile than Mineralys Therapeutics, Common. It trades about 0.02 of its total potential returns per unit of risk. Mineralys Therapeutics, Common is currently generating about 0.09 per unit of volatility. If you would invest  1,287  in Mineralys Therapeutics, Common on December 25, 2024 and sell it today you would earn a total of  390.00  from holding Mineralys Therapeutics, Common or generate 30.3% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

HCW Biologics  vs.  Mineralys Therapeutics, Common

HCW Biologics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in HCW Biologics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, HCW Biologics sustained solid returns over the last few months and may actually be approaching a breakup point.

Mineralys Therapeutics,

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively abnormal basic indicators, Mineralys Therapeutics, unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with HCW Biologics and Mineralys Therapeutics,

The main advantage of trading using opposite HCW Biologics and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if HCW Biologics position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.

The idea behind HCW Biologics and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.